Karyopharm Therapeutics is a mid-sized commercial-stage biopharmaceutical enterprise maintaining a dedicated workforce of several hundred specialized researchers, clinical operators, and commercial staff primarily headquartered in Newton, Massachusetts. Its operational scale encompasses active commercial sales of its approved oncology products, extensive laboratory facilities, and robust clinical trial operations spanning multiple international trial sites focused on advancing its proprietary selective inhibitor of nuclear export platform.